FTC settles three claims against Teva
Generic drugmaker Teva Pharmaceuticals has committed to refrain from resolving patent infringement disputes with pay-for-delay agreements that hamper generic competitors to brand-name drugs.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10